Khattar Jack A.'s Form 4 filing
Supernus Pharmaceuticals, Inc. (SUPN) · filed Mar 16, 2026
- Accession no.
- 0001539937-26-000008
- Filed
- Mar 16, 2026
- Trade date
- Mar 13, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions. Open-market sales total $1.76M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Khattar Jack A.CIK 0001539937 | Director, Officer (President, CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Common Stock | JOtherAcquired | +12,500 | –F1 | – | 1,241,144 | Direct | |
| Mar 13, 2026 | Common Stock | JOtherDisposed | −12,500 | –F1 | – | 993,100 | Indirect | |
| Mar 13, 2026 | Common Stock | SSaleDisposed | −24,138 | $50.09F3 | −$1,209,072.42 | 968,962 | Indirect | |
| Mar 13, 2026 | Common Stock | SSaleDisposed | −10,742 | $51.00F4 | −$547,842 | 958,220 | Indirect | |
| Mar 13, 2026 | Common Stock | SSaleDisposed | −120 | $51.75 | −$6,210 | 958,100 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly.
Referenced by the price of 2 transactions in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.63 to $50.62. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $51.54. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.